The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-like Growth Factor Signaling Pathway

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Sep 21

PMID 21931726

Citations 20

Authors

Rive Sarfstein

Ilan Bruchim

Ami Fishman

Haim Werner

Affiliations

Soon will be listed here.

Abstract

A correlation between components of the insulin-like growth factor (IGF) system and endometrial cancer risk has been shown in recent studies. The antitumor action of vorinostat, a histone deacetylase inhibitor, involves changes in the expression of specific genes via acetylation of histones and transcription factors. The aim of this study was to establish whether vorinostat can modify the expression of specific genes related to the IGF-I receptor (IGF-IR) signaling pathway and revert the transformed phenotype. Human endometrioid (Type I, Ishikawa) and uterine serous papillary (Type II, USPC-2) endometrial cancer cell lines were treated with vorinostat in the presence or absence of IGF-I. Vorinostat increased IGF-IR phosphorylation, produced acetylation of histone H3, up-regulated pTEN and p21 expression, and reduced p53 and cyclin D1 levels in Ishikawa cells. Vorinostat up-regulated IGF-IR and p21 expression, produced acetylation of histone H3, and down-regulated the expression of total AKT, pTEN and cyclin D1 in USPC-2 cells. Of interest, IGF-IR activation was associated with a major elevation in IGF-IR promoter activity. In addition, vorinostat treatment induced apoptosis in both cell lines and abolished the anti-apoptotic activity of IGF-I both in the absence or presence of a humanized monoclonal IGF-IR antibody, MK-0646. Finally, vorinostat treatment led to a significant decrease in proliferation and colony forming capability in both cell lines. In summary, our studies demonstrate that vorinostat exhibits a potent apoptotic and anti-proliferative effect in both Type I and II endometrial cancer cells, thus suggesting that endometrial cancer may be therapeutically targeted by vorinostat.

Citing Articles

Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat.

El Omari N, Khalid A, Makeen H, Alhazmi H, Albratty M, Mohan S Heliyon. 2024; 10(12):e33052.

PMID: 39021957 PMC: 11253278. DOI: 10.1016/j.heliyon.2024.e33052.

Gesicles packaging dCas9-VPR ribonucleoprotein complexes can combine with vorinostat and promote HIV proviral transcription.

Fisher M, Chaudhry W, Campbell L Mol Ther Methods Clin Dev. 2024; 32(1):101203.

PMID: 38390557 PMC: 10881426. DOI: 10.1016/j.omtm.2024.101203.

Deciphering the Role of Insulin-Like Growth Factor 1 in Endometrial Cancer in Patients With Polycystic Ovary Syndrome: Protocol for a Methodological Approach Using Cell Culture Experiments.

Atiomo W, Alqutami F, Albasha S, Hachim M JMIR Res Protoc. 2023; 12:e48127.

PMID: 37988160 PMC: 10698646. DOI: 10.2196/48127.

The Role of STATs in Ovarian Cancer: Exploring Their Potential for Therapy.

Standing D, Feess E, Kodiyalam S, Kuehn M, Hamel Z, Johnson J Cancers (Basel). 2023; 15(9).

PMID: 37173951 PMC: 10177275. DOI: 10.3390/cancers15092485.

PSRR: A Web Server for Predicting the Regulation of miRNAs Expression by Small Molecules.

Yu F, Li B, Sun J, Qi J, De Wilde R, Torres-de la Roche L Front Mol Biosci. 2022; 9:817294.

PMID: 35386297 PMC: 8979021. DOI: 10.3389/fmolb.2022.817294.

References

Kang-Park S, Lee Y, Lee Y . PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Lett. 2003; 545(2-3):203-8. DOI: 10.1016/s0014-5793(03)00535-0. View

Idrees M, Schlosshauer P, Li G, Burstein D . GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma. Histopathology. 2006; 49(1):75-81. DOI: 10.1111/j.1365-2559.2006.02447.x. View

Fulda S, Debatin K . HDAC inhibitors: double edge sword for TRAIL cancer therapy?. Cancer Biol Ther. 2005; 4(10):1113-5. DOI: 10.4161/cbt.4.10.2100. View

Pallares J, Martinez-Guitarte J, Dolcet X, Llobet D, Rue M, Palacios J . Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol. 2004; 204(5):569-77. DOI: 10.1002/path.1666. View

Richon V, Sandhoff T, Rifkind R, Marks P . Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A. 2000; 97(18):10014-9. PMC: 27656. DOI: 10.1073/pnas.180316197. View

Honda H, Nakamoto T, Sakai R, Hirai H . p130(Cas), an assembling molecule of actin filaments, promotes cell movement, cell migration, and cell spreading in fibroblasts. Biochem Biophys Res Commun. 1999; 262(1):25-30. DOI: 10.1006/bbrc.1999.1162. View

Lu K, Wu W, Dave B, Slomovitz B, Burke T, Munsell M . Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res. 2008; 14(9):2543-50. DOI: 10.1158/1078-0432.CCR-07-0321. View

Wozniak M, Villuendas R, Bischoff J, Aparicio C, Martinez Leal J, de la Cueva P . Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica. 2010; 95(4):613-21. PMC: 2857191. DOI: 10.3324/haematol.2009.013870. View

Mitsiades C, Mitsiades N, McMullan C, Poulaki V, Shringarpure R, Hideshima T . Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2003; 101(2):540-5. PMC: 327183. DOI: 10.1073/pnas.2536759100. View

10.

Zhao H, Dupont J, Yakar S, Karas M, LeRoith D . PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene. 2004; 23(3):786-94. DOI: 10.1038/sj.onc.1207162. View

11.

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

12.

LeRoith D, Werner H, Roberts Jr C . Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995; 16(2):143-63. DOI: 10.1210/edrv-16-2-143. View

13.

Juan L, Shia W, Chen M, Yang W, Seto E, Lin Y . Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem. 2000; 275(27):20436-43. DOI: 10.1074/jbc.M000202200. View

14.

Werner H, Bruchim I . The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem. 2009; 115(2):58-71. DOI: 10.1080/13813450902783106. View

15.

Hamilton C, Cheung M, Osann K, Chen L, Teng N, Longacre T . Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006; 94(5):642-6. PMC: 2361201. DOI: 10.1038/sj.bjc.6603012. View

16.

Gridelli C, Rossi A, Maione P . The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2008; 68(1):29-36. DOI: 10.1016/j.critrevonc.2008.03.002. View

17.

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

18.

Ashkenazi A . Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6):420-30. DOI: 10.1038/nrc821. View

19.

Hata H, Kuramoto H . Immunocytochemical determination of estrogen and progesterone receptors in human endometrial adenocarcinoma cells (Ishikawa cells). J Steroid Biochem Mol Biol. 1992; 42(2):201-10. DOI: 10.1016/0960-0760(92)90029-i. View

20.

Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon V . Vorinostat in solid and hematologic malignancies. J Hematol Oncol. 2009; 2:31. PMC: 2731787. DOI: 10.1186/1756-8722-2-31. View